HMS Holdings Corp (HMSY)
(Delayed Data from NSDQ)
$32.83 USD
+3.43 (11.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $32.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.83 USD
+3.43 (11.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $32.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
HMS Holdings (HMSY) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
HMS Holdings (HMSY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You Looking for a Top Momentum Pick? Why HMS Holdings (HMSY) is a Great Choice
by Zacks Equity Research
Does HMS Holdings (HMSY) have what it takes to be a top stock pick for momentum investors? Let's find out.
HMS Holdings (HMSY) to be Acquired by Gainwell for $3.4B
by Zacks Equity Research
HMS Holdings (HMSY) entered into an agreement to be acquired by Gainwell in an all-cash transaction deal worth about $3.4 billion.
HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.
HMS Holdings (HMSY) Matches Q3 Earnings Estimates
by Zacks Equity Research
HMS Holdings (HMSY) delivered earnings and revenue surprises of 0.00% and -3.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 6: ZBH, HRC and HMSY
by Urmimala Biswas
Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how ZBH, HRC and HMS are poised ahead of their announcements.
HMS Holdings (HMSY) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
HMS Holdings (HMSY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MDRX vs. HMSY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. HMSY: Which Stock Is the Better Value Option?
HMS Holdings (HMSY) Down 17.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HMS Holdings (HMSY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain HMS Holdings in Your Portfolio
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.
HMS Holdings (HMSY) Loses 2.9% Since Q2 Earnings Release
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB segment in Q2.
HMS Holdings (HMSY) Q2 Earnings Match Estimates
by Zacks Equity Research
HMS Holdings (HMSY) delivered earnings and revenue surprises of 0.00% and -7.42%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NXGN or HMSY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. HMSY: Which Stock Is the Better Value Option?
Analysts Estimate HMS Holdings (HMSY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HMS Holdings (HMSY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus
by Zacks Equity Research
Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.
ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment
by Zacks Equity Research
ABIOMED's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.
Here's Why You Should Add HMS Holdings to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) stock, thanks to solid prospects.
HMS Holdings' Solution to Help Consumers Amid Coronavirus
by Zacks Equity Research
HMS Holdings (HMSY) offers a unique COVID-19 health management and communications solution to support consumers during the pandemic.
PRA Health Boosts Health Harmony COVID-19 Monitoring Program
by Zacks Equity Research
PRA Health (PRAH) gives a boost to COVID-19 Monitoring program through collaboration with the Microsoft Healthcare Bot service.
HMSY or OMCL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HMSY vs. OMCL: Which Stock Is the Better Value Option?
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
Investor confidence is high in LHC Group (LHCG), thanks to solid prospects
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Will HMS Holdings Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of HMS Holdings
ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP
by Zacks Equity Research
This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.
Here's Why You Should Retain NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and solid recurring revenue base.